Multiple Myeloma | Specialty

Preventing Progression and Chasing Cure in Smoldering Myeloma

August 14th 2019

Data from several clinical trials support treatment with lenalidomide (Revlimid) plus low-dose dexamethasone in select patients with high-risk smoldering multiple myeloma to prevent disease progression and other promising combinations under investigation are showing curative potential.

Combinations Mark Future of Immunotherapy in Multiple Myeloma

August 14th 2019

The emergence of monoclonal antibodies, immunomodulatory agents, immunotoxins, bispecific T-cell engagers, and CAR T-cell therapies will redefine multiple myeloma treatment. However, these new approaches, by themselves, are not enough to achieve cure; they must be used in combination.

Dr. Rodriguez on Evolving Role of Small Molecules in Multiple Myeloma

August 14th 2019

Cesar Rodriguez Valdes, MD, assistant professor of Hematology and Oncology, Wake Forest University Comprehensive Cancer Center, highlights the evolving role of small molecules in multiple myeloma.

Multiagent Regimens Continue to Spearhead Progress in Late Relapsed Myeloma

August 14th 2019

Peter Voorhees, MD, discusses the recent data with triplet regimens in late relapsed multiple myeloma and other novel agents shaking up the paradigm.

Novel Induction Regimens Boost Survival in Newly Diagnosed Myeloma

August 13th 2019

The goal of induction regimens for patients with newly diagnosed multiple myeloma is to reduce the burden of disease and prolong durability of response and overall survival, while minimizing toxicity.

Identifying Patients and Treating With CAR T-Cell Therapy

August 13th 2019

Stem Cell Transplantation and Novel Therapy

August 13th 2019

Optimizing Therapy for Patients With Multiple Myeloma

August 13th 2019

Navigating Through Testicular Cancer Treatment

August 13th 2019

Relapsed Myeloma: With Great Options Comes Great Responsibility

August 9th 2019

Noopur Raje, MD, highlights the multitude of available and emerging options in relapsed myeloma, as well as the key factors for treatment selection in this heterogeneous population.

Dr. Chari on the Use of Frontline Daratumumab in Transplant-Eligible Patients With Myeloma

August 8th 2019

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the use of frontline daratumumab (Darzalex) in transplant-eligible patients with multiple myeloma.

Experts Discuss Highly Anticipated Study Results Across Tumor Types

August 5th 2019

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Dr. Gasparetto on Key Trials in Relapsed/Refractory Multiple Myeloma

August 2nd 2019

Cristina Gasparetto, MD, an associate professor of medicine, Duke University Medical Center, and director, Multiple Myeloma Program at Duke Cancer Institute, discusses key trials in relapsed/refractory multiple myeloma.

Dr. Cowan on the Role of Venetoclax in Multiple Myeloma

August 1st 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington and hematologist/oncologist at Seattle Cancer Care Alliance, discusses the role of venetoclax (Venclexta) in multiple myeloma.

QoL Comes Into Focus in Myeloma Amid Expanding Treatment Options

July 31st 2019

David Samuel Dicapua Siegel, MD, highlights key research in multiple myeloma and the renewed focus on improving quality of life.

Landgren Reflects on Recent Breakthroughs in Multiple Myeloma

July 30th 2019

C. Ola Landgren, MD, PhD, shares his expert insight on recent shifts in multiple myeloma management.

Dr. Chari on the E3A06 Trial in Smoldering Myeloma

July 29th 2019

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the phase III E3A06 study, which looked at the effects of lenalidomide in patients with smoldering myeloma.

Multiagent Regimens Progress Further in Frontline Myeloma

July 29th 2019

Kenneth C. Anderson, MD, discusses available and emerging frontline treatment regimens for patients with newly diagnosed multiple myeloma and evaluated the utility of minimal residual disease in the paradigm.

Elotuzumab Triplet Approaches EU Approval for Multiple Myeloma

July 29th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approving elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor.

Quadruplet Regimens Show Promising Activity in Multiple Myeloma

July 26th 2019

Ajai Chari, MD, discusses current and emerging research in patients with transplant-eligible and -ineligible multiple myeloma as well as updates in smoldering multiple myeloma.